LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended Delisting and Cancellation of its Ordinary Shares from Trading on AIM, as announced on September 21, 2020.
Read the rest here:
Verona Pharma plc : Update on AIM Delisting
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter of 2020 and provide a corporate update at 4:30 p.m. ET on November 4, 2020.
Follow this link:
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Oct. 28, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today the award of a German Federal Government grant to its subsidiary, Curetis GmbH, and collaborators Carpegen GmbH (Muenster, Germany) and the Clinic for Small Animal Internal Medicine of the LMU Ludwig-Maximilians- University (Munich, Germany).
See the original post:
OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators
SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:
Read this article:
Iovance Biotherapeutics to Present at Upcoming Conferences in November
Vancouver, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, today provided the following update regarding how it expects to overcome potential challenges of recruiting patients for human trials.
Read the rest here:
BetterLife Provides Important Update on its Australian Clinical Study Design
-Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-
Go here to read the rest:
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
Continued here:
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
WINNIPEG, Manitoba, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) is pleased to announce that the launch of a larger consumer product test to further prove the efficacy of the Company’s shampoo on dermatitis and dandruff began on October 14, 2020.
Read this article:
Kane Biotech builds upon successful results with launch of a US Consumer Test
Read this article:
Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, today announced it has initiated two pilot clinical studies to demonstrate effectiveness of an AAV expressing a GLP-1 analog (SB-009) in treating diabetic felines.
See the article here:
Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes
WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the presentation of preclinical data highlighting the potential of its modular biologics pipeline for the treatment of autoimmune diseases at the Federation of Clinical Immunology Societies (FOCIS) 2020 virtual annual meeting.
Continue reading here:
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
WOBURN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has begun field testing to evaluate the emergence and agronomics of winter Camelina sativa varieties. The testing of these winter varieties in the 2020/2021 winter season is part of Yield10’s continued development of Camelina sativa in the medium term for use at commercial scale as a cash cover crop for North America.
Continue reading here:
Yield10 Bioscience Announces Start of Field Tests of Winter Camelina Varieties
LAS VEGAS, NV, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Pharma Inc. (OTC: OWPC), “OWP,” a U.S. based, fully licensed, pure-play hemp and cannabis ingredient producer in Colombia, is pleased to announce that its Executive Chairman, Dr. Kenneth Perego, recently joined television personality and cannabis advocate Montel Williams on his popular podcast “Let’s Be Blunt.”
Continued here:
One World’s Dr. Kenneth Perego Joins Montel Williams for Blunt Discussion
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.
Follow this link:
AXIM® Biotechnologies Issues Update Letter to Shareholders
Please read the full announcement in PDF
Follow this link:
Trading by management and close relations of management
CALGARY, Alberta, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces that, further to its October 9, 2020 press release, it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the “Interim Filings”). These filings can be found at www.sedar.com under the Company’s profile.
See the original post here:
Zenith Confirms Interim Filings on SEDAR
The Company’s Flagship Brand Tauri-Gum™ is Fully Compliant With the New Rules Set Out This Week by New York State (“New York”)
MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.
More:
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.
More here:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share. The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.
Read the original here:
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock